Eli Lilly’s anti-amyloid beta monoclonal antibody (mAb) Kisunla (donanemab) has become the second disease-modifying therapy for Alzheimer’s disease (AD) to reach the US market, following approval by the US Food and Drug Administration (FDA). It has been approved by the regulator for the treatment of patients with mild cognitive impairment (MCI) or mild AD with […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!